A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers.
HPV serostatus
head and neck cancer risk
polygenic risk score
risk prediction models
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 05 2023
15 05 2023
Historique:
revised:
21
12
2022
received:
10
04
2022
accepted:
23
12
2022
pubmed:
26
1
2023
medline:
15
3
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Head and neck cancer is often diagnosed late and prognosis for most head and neck cancer patients remains poor. To aid early detection, we developed a risk prediction model based on demographic and lifestyle risk factors, human papillomavirus (HPV) serological markers and genetic markers. A total of 10 126 head and neck cancer cases and 5254 controls from five North American and European studies were included. HPV serostatus was determined by antibodies for HPV16 early oncoproteins (E6, E7) and regulatory early proteins (E1, E2, E4). The data were split into a training set (70%) for model development and a hold-out testing set (30%) for model performance evaluation, including discriminative ability and calibration. The risk models including demographic, lifestyle risk factors and polygenic risk score showed a reasonable predictive accuracy for head and neck cancer overall. A risk model that also included HPV serology showed substantially improved predictive accuracy for oropharyngeal cancer (AUC = 0.94, 95% CI = 0.92-0.95 in men and AUC = 0.92, 95% CI = 0.88-0.95 in women). The 5-year absolute risk estimates showed distinct trajectories by risk factor profiles. Based on the UK Biobank cohort, the risks of developing oropharyngeal cancer among 60 years old and HPV16 seropositive in the next 5 years ranged from 5.8% to 14.9% with an average of 8.1% for men, 1.3% to 4.4% with an average of 2.2% for women. Absolute risk was generally higher among individuals with heavy smoking, heavy drinking, HPV seropositivity and those with higher polygenic risk score. These risk models may be helpful for identifying people at high risk of developing head and neck cancer.
Identifiants
pubmed: 36694401
doi: 10.1002/ijc.34444
pmc: PMC10006331
mid: NIHMS1868569
doi:
Substances chimiques
Genetic Markers
0
Antibodies, Viral
0
Transcription Factors
0
Oncogene Proteins, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2069-2080Subventions
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025712
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA090731
Pays : United States
Organisme : Cancer Research UK
ID : C18281/A19169
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA097190
Pays : United States
Organisme : Department of Health
ID : RP-PG-0707-10034
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N005872/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 UICC.
Références
Am J Epidemiol. 2012 Jun 15;175(12):1225-33
pubmed: 22575416
Cancer Causes Control. 2010 Dec;21(12):2213-21
pubmed: 20835759
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
PLoS One. 2020 Aug 28;15(8):e0237723
pubmed: 32857771
Vital Health Stat 10. 2012 Jan;(252):1-207
pubmed: 22834228
CA Cancer J Clin. 2016 May;66(3):203-39
pubmed: 27002678
J Am Dent Assoc. 2008 Jul;139(7):896-905; quiz 993-4
pubmed: 18594075
Ann Oncol. 2019 Aug 1;30(8):1335-1343
pubmed: 31185496
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):683-9
pubmed: 25623733
Cancer Sci. 2020 Oct;111(10):3835-3844
pubmed: 32662535
J Clin Oncol. 2013 Jul 20;31(21):2708-15
pubmed: 23775966
Ann Intern Med. 2014 Jan 7;160(1):55-60
pubmed: 24276469
Int J Epidemiol. 2016 Jun;45(3):835-45
pubmed: 26228584
PLoS One. 2020 Feb 5;15(2):e0228198
pubmed: 32023287
Lifetime Data Anal. 2008 Mar;14(1):18-36
pubmed: 18058231
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376197
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
Int J Cancer. 2018 Sep 1;143(5):1114-1127
pubmed: 29607493
Int J Epidemiol. 2016 Jun;45(3):752-61
pubmed: 27197530
J Natl Cancer Inst. 2007 May 16;99(10):777-89
pubmed: 17505073
Cancer Epidemiol. 2016 Jun;42:173-80
pubmed: 27173062
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
Oral Oncol. 2020 Sep;108:104736
pubmed: 32502860
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Eur J Cancer Prev. 2017 Jan;26(1):38-47
pubmed: 26862830
Cancer. 2017 May 1;123(9):1597-1609
pubmed: 28055109
Int J Oncol. 2020 Nov;57(5):1192-1202
pubmed: 33491742
Am J Epidemiol. 2020 Apr 2;189(4):330-342
pubmed: 31781743
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012
pubmed: 30445434
Oral Oncol. 2013 Apr;49(4):314-21
pubmed: 23265945
Cancers (Basel). 2021 Jun 16;13(12):
pubmed: 34208476
Cancer. 2018 May 1;124(9):1859-1866
pubmed: 29499070
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Dent Clin North Am. 2018 Jan;62(1):143-154
pubmed: 29126491
EBioMedicine. 2020 Dec;62:103123
pubmed: 33248371
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Ann Oncol. 2019 May 1;30(5):744-756
pubmed: 30840052
PLoS Genet. 2011 Mar;7(3):e1001333
pubmed: 21437268
Cancer Epidemiol. 2013 Aug;37(4):417-23
pubmed: 23619143
Nat Genet. 2016 Dec;48(12):1544-1550
pubmed: 27749845
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Nat Commun. 2021 Oct 12;12(1):5945
pubmed: 34642315
Cochrane Database Syst Rev. 2013 Nov 19;(11):CD004150
pubmed: 24254989